Ascentage Pharma Group International (NASDAQ:AAPG) Sees Strong Trading Volume – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw an uptick in trading volume on Friday . 3,938 shares were traded during trading, a decline of 13% from the previous session’s volume of 4,552 shares.The stock last traded at $17.6950 and had previously closed at $17.11.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research report on Wednesday. They issued a “buy” rating and a $45.00 price objective for the company. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Up 4.2%

The business’s 50-day moving average price is $22.27 and its two-hundred day moving average price is $24.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter. Research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $383,000. XY Capital Ltd grew its holdings in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the period. UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International in the third quarter valued at approximately $204,000. Finally, Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the second quarter valued at approximately $391,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.